SCYX

Scynexis Inc

3.52

Nov 10 • 3:59 PM ET +0.02 (0.57%)

3.52

Aftermarket • 5:00 PM ET 0.00 (0.00%)

Healthcare Drug Manufacturers - Specialty & Generic USA Nano NASD

Peers: CPIX MTNB SPRO DARE ARMP ACXP ANTX TNXP FEMY VIR

| Held by: VTI VXF BSVO DFAS DFMC DXUV

Scroll to Statements

Index	-
Market Cap	35.04M
Enterprise Value	-10.44M
Income	-10.10M
Sales	18.88M
Book/sh	5.93
Cash/sh	4.75
Dividend Est.	-
Dividend TTM	-
Dividend Ex-Date	-
Dividend Gr. 3/5Y	- -
Payout	-
Employees	18
IPO	May 02, 2014

P/E	-
Forward P/E	-
PEG	-
P/S	1.86
P/B	0.59
P/C	0.74
P/FCF	-
EV/EBITDA	-
EV/Sales	-0.55
Quick Ratio	7.48
Current Ratio	7.48
Debt/Eq	0.03
LT Debt/Eq	0.02
Option/Short	Yes / Yes

EPS (ttm)	-1.18
EPS next Y	-1.95
EPS next Q	-0.63
EPS this Y	-130.15%
EPS next Y	37.59%
EPS next 5Y	-8.35%
EPS past 3/5Y	51.09% 49.30%
Sales past 3/5Y	59.35% -
EPS Y/Y TTM	72.49%
Sales Y/Y TTM	543.96%
EPS Q/Q	48.15%
Sales Q/Q	-100.00%
Earnings	Nov 05 BMO
EPS/Sales Surpr.	1.39% -100.00%

Insider Own	3.96%
Insider Trans	0.00%
Inst Own	56.69%
Inst Trans	13.06%
ROA	-16.98%
ROE	-21.16%
ROIC	-16.75%
Gross Margin	-
Oper. Margin	-126.87%
Profit Margin	-53.50%
SMA20	-6.11%
SMA50	-18.53%
SMA200	-35.66%
Trades

Shs Outstand	9.95M
Shs Float	9.56M
Short Float	4.71%
Short Ratio	2.02
Short Interest	0.45M
52W High	9.12 -61.40%
52W Low	3.28 7.31%
Volatility	7.01% 5.80%
ATR (14)	0.26
RSI (14)	37.81
Beta	1.23
Rel Volume	0.17
Avg Volume	222.71K
Volume	37,357

Perf Week	-10.66%
Perf Month	-12.66%
Perf Quarter	-26.82%
Perf Half Y	-43.59%
Perf YTD	-30.42%
Perf Year	-26.67%
Perf 3Y	-74.19%
Perf 5Y	-92.24%
Perf 10Y	-98.78%
Recom	1.00
Target Price	32.67
Prev Close	3.50
Price	3.52
Change %	0.57%

Consensus

Strong Buy

Avg. Price Target

$32.67

Implied Upside

+828.1%

Analysts9incl. previous ratings

Rating Distribution9 Buy · 0 Hold · 0 Sell

Date	Action	Analyst	Rating Change	Price Target Change	Implied Upside
Jan 22, 2021	Initiated	GGuggenheim	Buy	$25	+610.2%
Jan 06, 2021	Initiated	CCantor Fitzgerald	Overweight	$30	+752.3%
Jul 11, 2018	Upgrade	NNeedham	Hold → Buy	$5	+42.0%
Jun 27, 2018	Initiated	MMaxim Group	Buy	$6	+70.5%
Oct 24, 2017	Initiated	GGuggenheim	Buy	$6	+70.5%
Jul 10, 2017	Initiated	RROTH Capital	Buy	$8.50	+141.5%
May 09, 2017	Downgrade	NNeedham	Buy → Hold
Mar 03, 2017	Reiterated	RRBC Capital Mkts	Outperform	$15 → $11	+212.5%
Oct 20, 2016	Initiated	HH.C. Wainwright	Buy	$14	+297.7%
Oct 07, 2016	Upgrade	WWBB Securities	Buy → Strong Buy	$8	+127.3%
Oct 03, 2016	Resumed	BBrean Capital	Buy
Aug 17, 2016	Initiated	GGuggenheim	Buy	$15	+326.1%
Aug 09, 2016	Upgrade	WWBB Securities	Speculative Buy → Buy	$8	+127.3%
Aug 09, 2016	Reiterated	NNeedham	Buy	$16 → $10	+184.1%
Mar 28, 2016	Initiated	BBrean Capital	Buy	$16	+354.5%
Dec 29, 2015	Initiated	WWBB Securities	Strong Buy	$8	+127.3%
Dec 29, 2015	Initiated	WWBB Securities	Speculative Buy	$8	+127.3%
Nov 16, 2015	Reiterated	RRBC Capital Mkts	Outperform	$18 → $17	+383.0%
Jun 10, 2015	Initiated	NNeedham	Buy	$16	+354.5%
May 29, 2014	Initiated	RRBC Capital Mkts	Outperform	$17	+383.0%

Nov-05-26 08:27AM	Scynexis: Q3 Earnings Snapshot (Associated Press) -14.06%
08:20AM	SCYNEXIS Reports Third Quarter 2026 Financial Results and Provides Corporate Update (GlobeNewswire)
Oct-29-26 08:00AM	SCYNEXIS to Participate in the 3rd Annual Guggenheim Healthcare Innovation Conference (GlobeNewswire)
Oct-22-26 08:00AM	SCYNEXIS Completes Phase 1 Study of Intravenous SCY-247, a Novel, Triterpenoid Antifungal in Development for Treatment and Prevention of Invasive Fungal Diseases (GlobeNewswire)
Oct-21-26 04:05PM	SCYNEXIS to Feature SCY-247 in a Pipeline Presentation at IDWeek (GlobeNewswire)
07:30AM	Loading…
Oct-06-26 07:30AM	SCYNEXIS Announces Phase 1 Study Results for SCY-770, a Novel, Highly Selective, Oral Direct AMPK Activator for the Treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD) (GlobeNewswire)
Sep-28-26 09:58AM	Scynexis stock surges on $214M BARDA contract for SCY-247 (Investing.com) +5.24%
08:10AM	Scynexis Shares Rise 13.9% After BARDA Awards SCY-247 Development Contract (InvestorsHub)
07:30AM	SCYNEXIS Awarded BARDA Contract Providing Up to $214 Million in Non-Dilutive Funding for the Development of SCY-247 (GlobeNewswire)
Sep-22-26 08:00AM	SCYNEXIS Appoints Seasoned Industry Veteran Steven K. Burke, M.D., to its Board of Directors (GlobeNewswire) +10.45%
Sep-15-26 08:00AM	SCYNEXIS Appoints Todd Minga, M.D., as Senior Vice President, Research & Development (GlobeNewswire)
Sep-10-26 08:00AM	SCYNEXIS Announces Appointment of Sanjay Subramanian as Chief Financial Officer (GlobeNewswire)
Sep-01-26 08:30AM	SCYNEXIS to Participate in Upcoming Investor Conferences (GlobeNewswire)
Aug-25-26 07:06PM	SCYNEXIS Announces Inducement Award Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire) +9.25%
Aug-10-26 04:56PM	Scynexis: Q2 Earnings Snapshot (Associated Press) -6.21%
04:30PM	Loading…
04:30PM	SCYNEXIS Reports Second Quarter 2026 Financial Results and Provides Corporate Update (GlobeNewswire)
Jun-30-26 08:00AM	SCYNEXIS Initiates Phase 1 Study of SCY-770, a Novel AMPK Activator for the Treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD) (GlobeNewswire) +5.17%
May-22-26 04:15PM	SCYNEXIS Announces One-for-Eight Reverse Stock Split (GlobeNewswire) -6.88%
May-11-26 04:43PM	Scynexis: Q1 Earnings Snapshot (Associated Press) -10.00% -5.35%
04:23PM	SCYNEXIS Reports First Quarter 2026 Financial Results and Provides Corporate Update (GlobeNewswire)
May-06-26 09:15PM	SCYNEXIS Announces Inducement Awards Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Mar-31-26 07:06AM	Poxel Announces the Sale of PXL770 to Scynexis for a Total Amount of up to $196 Million (Business Wire) +16.11%
06:45AM	SCYNEXIS Announces $40.0 Million Private Placement (GlobeNewswire)
06:40AM	SCYNEXIS Completes Transformative Acquisition of PXL-770, an innovative, highly selective, direct AMPK activator for the Treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD) (GlobeNewswire)
Mar-04-26 05:36PM	Scynexis: Q4 Earnings Snapshot (Associated Press Finance)
04:20PM	SCYNEXIS Reports Full Year 2025 Financial Results and Provides Corporate Update (GlobeNewswire)
Feb-26-26 08:23AM	SCYNEXIS Announces First Participants Dosed in a Phase 1 Single Ascending Dose and Multiple Ascending Dose Trial of Intravenous SCY-247 (GlobeNewswire)
Jan-28-26 08:00AM	SCYNEXIS Announces Presentations Highlighting the Potent Antifungal Activity of its Second-Generation Fungerp, SCY-247 Against Drug-Resistant Fungi, at the Inaugural Interdisciplinary Meeting on Antimicrobial Resistance and Innovation (IMARI) (GlobeNewswire)
Jan-21-26 08:00AM	SCYNEXIS Receives FDA Qualified Infectious Disease Product (QIDP) and Fast Track Designations for SCY-247 (GlobeNewswire)
Dec-22-25 08:00AM	SCYNEXIS Granted 180-Day Extension by Nasdaq to Regain Compliance with Minimum Bid Price Requirement (GlobeNewswire)
07:00AM	Loading…
Nov-19-25 07:00AM	SCYNEXIS Completes Transfer of BREXAFEMME New Drug Application to GSK (GlobeNewswire)
Nov-17-25 10:15AM	Scynexis Announces Federal Funding of Collaboration Between Hackensack Meridian CDI and Johns Hopkins Researchers to Develop New Therapeutics, Including Novel Fungerps, for Resistant Fungal Infections (GlobeNewswire)
Nov-05-25 04:51PM	Scynexis: Q3 Earnings Snapshot (Associated Press Finance) -5.48%
04:20PM	SCYNEXIS Reports Third Quarter 2025 Financial Results and Provides Corporate Update (GlobeNewswire)
Oct-24-25 08:07AM	SCYNEXIS Reports Positive Phase 1 Results for Second-Generation Antifungal SCY-247 (Insider Monkey)
Oct-15-25 08:00AM	SCYNEXIS and GSK Resolve Their Disagreement Related to the Restart of the Phase 3 MARIO Study (GlobeNewswire)
Oct-01-25 07:10AM	SCYNEXIS announces favourable Phase I data for SCY-247 trial (Clinical Trials Arena)
Sep-30-25 08:00AM	SCYNEXIS Announces Positive Results from a Phase 1, Single Ascending Dose and Multiple Ascending Dose Study of its Second-Generation Fungerp (SCY-247) (GlobeNewswire) -26.67%
Sep-04-25 08:30AM	SCYNEXIS Announces Multiple Presentations Highlighting Data from its Second-Generation Fungerp, SCY-247, at the 12th Congress on Trends in Medical Mycology (TIMM-12) (GlobeNewswire)
Aug-25-25 08:00AM	SCYNEXIS to Participate in the H.C. Wainwright 27th Annual Global Conference September 8 - 10, 2025 (GlobeNewswire)
Aug-13-25 04:35PM	Scynexis: Q2 Earnings Snapshot (Associated Press Finance) -5.15%
04:30PM	SCYNEXIS Reports Second Quarter 2025 Financial Results and Provides Corporate Update (GlobeNewswire)
May-29-25 12:31AM	SCYNEXIS, Inc. (SCYX) Resumes Phase III Dosing for Brexafemme After 19-Month FDA Hold (Insider Monkey)
May-28-25 12:23PM	Scynexis resumes dosing in Phase III MARIO study after lengthy delay (Clinical Trials Arena) +28.04%
08:30AM	SCYNEXIS Resumes Patient Dosing in Phase 3 MARIO Study (GlobeNewswire)
May-15-25 04:56PM	Scynexis: Q1 Earnings Snapshot (Associated Press Finance) -19.29%
04:20PM	SCYNEXIS Reports First Quarter 2025 Financial Results and Provides Corporate Update (GlobeNewswire)
Apr-08-25 08:00AM	SCYNEXIS to Present Preclinical Data on Second Generation IV/Oral Fungerp SCY-247 at the European Society of Clinical Microbiology and Infectious Diseases (ESCMID) (GlobeNewswire)
Mar-12-25 05:08PM	SCYNEXIS Reports Full Year 2024 Financial Results and Provides Corporate Update (GlobeNewswire) -5.90%
Dec-18-24 08:00AM	SCYNEXIS Initiates Dosing in Phase 1 Trial of SCY-247, a Second-Generation Fungerp Candidate for Invasive Fungal Infections (GlobeNewswire) -9.01%
Nov-06-24 05:55PM	Scynexis: Q3 Earnings Snapshot (Associated Press Finance)
04:30PM	SCYNEXIS Reports Third Quarter 2024 Financial Results and Provides Corporate Update (GlobeNewswire)
Oct-10-24 08:00AM	SCYNEXIS to Participate in the 2024 Maxim Healthcare Virtual Summit (GlobeNewswire)
Oct-07-24 05:02PM	Federated Hermes, Inc. Expands Stake in SCYNEXIS Inc (GuruFocus.com)
Oct-03-24 08:00AM	SCYNEXIS to Present Preclinical Data on Second Generation Fungerp SCY-247 at IDWeek 2024 (GlobeNewswire)
Aug-27-24 08:00AM	SCYNEXIS to Participate in H. C. Wainwright 26th Annual Global Investment Conference (GlobeNewswire) -5.73%
Aug-08-24 05:44PM	Scynexis: Q2 Earnings Snapshot (Associated Press Finance) -7.85%
04:30PM	SCYNEXIS Reports Second Quarter 2024 Financial Results and Provides Corporate Update (GlobeNewswire)
Jul-23-24 07:00AM	SCYNEXIS to Receive $10 Million Milestone Payment from GSK Triggered by Delivery of Completed FURI, CARES and NATURE Clinical Study Reports (GlobeNewswire)
Jul-22-24 06:24AM	3 Stocks Under $10 With the Potential for Massive Gains (InvestorPlace)
Jul-11-24 07:00AM	3 Dirt-Cheap Drug Developers With Blockbuster Potential (InvestorPlace) +12.69%
Jul-01-24 02:18PM	7 Undervalued Biotech Stocks to Buy for Big-Time Returns (InvestorPlace)
May-31-24 11:50AM	Hidden Gems: 3 Under-$10 Stocks Poised for 500% Growth by 2025 (InvestorPlace)
May-23-24 06:42AM	3 Stocks Under $10 With Mammoth Growth Prospects (InvestorPlace) -11.46%
May-08-24 11:54PM	SCYX Stock Earnings: SCYNEXIS Beats EPS, Misses Revenue for Q1 2024 (InvestorPlace)
04:51PM	Scynexis: Q1 Earnings Snapshot (Associated Press Finance)
04:30PM	SCYNEXIS Reports First Quarter 2024 Financial Results and Provides Corporate Update (GlobeNewswire)
Apr-30-24 04:05PM	SCYNEXIS Presented Preclinical Data on Second Generation Fungerp SCY-247 at the Congress of the European Society of Clinical Microbiology and Infectious Diseases (ESCMID Global, Formerly ECCMID) (GlobeNewswire) -7.14%
Apr-16-24 11:52AM	14 Cheap Penny Stocks to Buy According to Analysts (Insider Monkey)
Apr-09-24 04:05PM	SCYNEXIS to Present Preclinical Data on Second Generation Fungerp SCY-247 at the 34th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID) (GlobeNewswire)
Mar-28-24 11:53PM	SCYX Stock Earnings: SCYNEXIS Misses EPS, Beats Revenue for Q4 2023 (InvestorPlace)
04:01PM	SCYNEXIS Reports Full Year 2023 Financial Results and Provides Corporate Update (GlobeNewswire)
Jan-30-24 04:05PM	SCYNEXIS to Participate in Guggenheim's 6th Annual Biotechnology Conference (GlobeNewswire) +5.37%
Jan-29-24 05:15PM	SCYNEXIS Presented Preclinical Data on Second Generation Fungerp SCY-247 against Mucormycosis at the 11th Advances Against Aspergillosis and Mucormycosis Conference (GlobeNewswire)
Jan-05-24 08:30AM	SCYNEXIS to Present Preclinical Data on Second Generation Fungerp SCY-247 at the 11th Advances Against Aspergillosis and Mucormycosis Conference, January 25 27, in Milan, Italy (GlobeNewswire)
Dec-27-23 09:30AM	SCYNEXIS SHAREHOLDER NOTICE: Faruqi & Faruqi Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $25,000 In Scynexis To Contact Him Directly To Discuss Their Options (GlobeNewswire)
Nov-27-23 10:33AM	11 Cheapest Stocks With Biggest Upside (Insider Monkey)
Nov-15-23 01:15PM	SCYX STOCKHOLDERS: Contact Robbins LLP for Information About Your Rights Against Scynexis, Inc. (Business Wire)
Nov-13-23 05:55PM	Scynexis: Q3 Earnings Snapshot (Associated Press Finance)
05:17PM	SCYNEXIS Reports Third Quarter 2023 Financial Results and Provides Corporate Update (GlobeNewswire)
Oct-24-23 08:00AM	SCYNEXIS Presents New Preclinical Data on Second Generation Fungerp SCY-247 at the 11th Congress on Trends in Medical Mycology (TIMM) (GlobeNewswire)
Oct-18-23 09:00PM	Bragar Eagel & Squire, P.C. Is Investigating Orthofix, and Scynexis and Encourages Investors to Contact the Firm (GlobeNewswire)
Oct-16-23 08:00AM	SCYNEXIS to Present Preclinical Data on Second Generation Fungerp SCY-247 at the 11th Congress on Trends in Medical Mycology (TIMM) October 20-23 in Athens, Greece (GlobeNewswire) +6.12%
Oct-02-23 09:00PM	Bragar Eagel & Squire, P.C. Is Investigating Orthofix, and Scynexis and Encourages Investors to Contact the Firm (GlobeNewswire)
Sep-27-23 08:31PM	SCYNEXIS Issues a Voluntary Nationwide Recall of BREXAFEMME® (ibrexafungerp tablets) due to potential for cross contamination with a non-antibacterial ß-lactam drug substance (GlobeNewswire) +9.33% +9.00%
07:49AM	Verve Therapeutics (VERV) Soars 13.8%: Is Further Upside Left in the Stock? (Zacks)
Sep-25-23 08:55AM	UPDATE 4-Scynexis to recall GSK-partnered antifungal on cross contamination risk (Reuters) -34.14%
Sep-20-23 04:00AM	PTC Therapeutics (PTCT) Surges 5.8%: Is This an Indication of Further Gains? (Zacks) +5.01%
Sep-04-23 01:31PM	SCYNEXIS (SCYX) Skyrockets 134% Year to Date: Here's Why (Zacks)
Aug-28-23 10:17PM	Want to Get Rich? 3 Game-Changing Penny Stocks to Buy Right Now (InvestorPlace) +11.96%
08:00AM	SCYNEXIS to Participate in September Investor Conferences (GlobeNewswire)
Aug-14-23 04:59PM	Scynexis: Q2 Earnings Snapshot (AP Finance) -6.35%
04:30PM	SCYNEXIS Reports Second Quarter 2023 Financial Results and Provides Corporate Update (GlobeNewswire)
Aug-11-23 09:09AM	10 Best Fast Growing Penny Stocks to Buy Now (Insider Monkey)
Jul-20-23 09:58AM	SCYNEXIS and Hansoh Pharma Announce NMPA Acceptance of the New Drug Application for Ibrexafungerp in China (GlobeNewswire) +5.69%
Jun-26-23 02:20PM	Deadly Fungi Are Becoming More Common and Were Running Out of Ways to Treat Them (The Wall Street Journal)
07:00AM	Doctors Desperately Need Drugs to Kill Deadly Fungi. Its an Uphill Fight. (The Wall Street Journal)
Jun-21-23 07:00AM	SCYNEXIS Announces Achievement of First Development Milestone of $25 Million Under Exclusive License Agreement with GSK (GlobeNewswire)
Jun-15-23 04:10PM	SCYNEXIS to Participate in the Maxim Group Virtual Healthcare Conference (GlobeNewswire)
May-19-23 09:22AM	WBB Research Institute Webcast Highlighted the Need For a Global Response to Candida auris and Other Deadly Antimicrobial Resistant Pathogens (Newsfile)

Show Previous News

SCYNEXIS, Inc. is a biotechnology company, which engages in the development of novel oral and intravenous triterpenoid antifungal for the treatment of several fungal infections, including vulvovaginal candidiasis, invasive aspergillosis, invasive candidiasis, and refractory invasive fungal infections. The company was founded by Scot Kevin Huber, Terry Eugene Marquardt, Pierre Bernard Jacques Monnet, Russell J. Outcalt, and Yves Joseph Ribeill on November 4, 1999 and is headquartered in Jersey City, NJ.

CEODr. David Gonzalez Angulo M.D.

Chief Legal Officer & Corporate SecretaryMr. Scott Sukenick J.D.

M.S.Mr. Sanjay S. Subramanian M.B.A.

Vice President of Human Resources & Information TechnologyMs. Daniella Gigante

Senior Vice President of Research & DevelopmentDr. Todd Minga M.D.

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

SCYX

Scynexis Inc

Upgrade your Finviz experience